Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR plus MBC)

被引：0
|
作者：
Blakely, L. J.
Schwartzberg, L. S.
Wang, G.
Somer, B. G.
Wheeler, B. M.
Stepanski, E. J.
Walker, M.
Johns, A.
机构：
[1] West Clin, Memphis, TN USA
[2] Adv Med Specialties, Miami, FL USA
[3] ACORN Res, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11087
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
    Zhao, Jianli
    Yu, Yunfang
    Ren, Wei
    Ding, Linxiaoxiao
    Chen, Yongjian
    Yuan, Peng
    Yue, Jian
    Yang, Yaping
    Zou, Guorong
    Chen, Tao
    Chai, Jie
    Zhang, Li
    Wu, Wenjing
    Zeng, Yinduo
    Gui, Xiujuan
    Cai, Yangyang
    Luo, Simin
    Yuan, Zhongyu
    Zhang, Kang
    Yao, Herui
    Wang, Ying
    MEDCOMM, 2025, 6 (01):
  • [42] Patterns of care and patient characteristics in postmenopausal women with HER2+and hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Sharma, P. P.
    Sail, K.
    Delea, T. E.
    Forsyth, M. T.
    Halm, M.
    Nagarwala, Y. M.
    Lopez, W.
    Patt, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Walker, Amanda J.
    Wedam, Suparna
    Amiri-Kordestani, Laleh
    Bloomquist, Erik
    Tang, Shengui
    Sridhara, Rajeshwari
    Chen, Wei
    Palmby, Todd R.
    Zirkelbach, Jeanne Fourie
    Fu, Wentao
    Liu, Qi
    Tilley, Amy
    Kim, Geoffrey
    Kluetz, Paul G.
    McKee, Amy E.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 4968 - 4972
  • [44] Multicentric phase II trial of gemcitabine plus capecitabine combination in the treatment of previously anthracycline(An)-treated metastatic breast cancer (MBC): SOLTI 0301 study
    Ciruelos, E. M.
    Baselga, J.
    Cortes-Funes, H.
    Lluch, A.
    Mayordomo, J. I.
    Ojeda, B.
    Gonzalez, E.
    Munoz, M.
    Rodriguez, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Neratinib plus fulvestrant plus trastzuzumab (N plus F plus T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.
    Jhaveri, Komal L.
    Goldman, Jonathan W.
    Hurvitz, Sara A.
    Guerrero-Zotano, Angel
    Unni, Nisha
    Brufsky, Adam
    Park, Haeseong
    Waisman, James Ross
    Yang, Eddy Shih-Hsin
    Spanggaard, Iben
    Reid, Sonya A.
    Burkard, Mark E.
    Prat, Aleix
    Loi, Sherene
    Crown, John
    Hanker, Ariella
    Ma, Cynthia X.
    Bose, Ron
    Eli, Lisa DeFazio
    Wildiers, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Pyrotinib combined with fulvestrant in women with hormone receptor-positive (HR plus ) and human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer: A single-arm phase II clinical trial
    Wang, Ying
    Zhao, Jianli
    Yuan, Zhongyu
    Zou, Guorong
    Li, Haiyan
    Ding, Linxiaoxiao
    Yang, Yaping
    Chai, Jie
    Liu, Donggeng
    Yao, Herui
    CANCER RESEARCH, 2022, 82 (04)
  • [47] Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial
    Montagna, Emilia
    Palazzo, Antonella
    Maisonneuve, Patrick
    Cancello, Giuseppe
    Iorfida, Monica
    Sciandivasci, Angela
    Esposito, Angela
    Cardillo, Anna
    Mazza, Manuelita
    Munzone, Elisabetta
    Lai, Antonella
    Goldhirsch, Aron
    Colleoni, Marco
    CANCER LETTERS, 2017, 400 : 276 - 281
  • [48] Phase II trial of palbociclib plus endocrine therapy followed by combination of pembrolizumab, palbociclib and endocrine therapy in patients with hormone receptor positive metastatic breast cancer
    Yuan, Yuan
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Stewart, Daphne
    Waisman, James
    Yap, Kelly
    Mortimer, Joanne
    Tank, Niki
    CANCER RESEARCH, 2023, 83 (05)
  • [49] A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
    Traina, TA
    Dickler, MN
    Caravelli, JF
    Yeh, BM
    Brogi, E
    Panageas, K
    Flores, SA
    Norton, L
    Park, J
    Hudis, C
    Rugo, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S93 - S94
  • [50] Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Egelston, Colt A.
    Guo, Weihua
    Padam, Simran
    Tang, Aileen
    Martinez, Norma
    Schmolze, Daniel
    Presant, Cary
    Ebrahimi, Behnam
    Yeon, Christina
    Sedrak, Mina
    Patel, Niki
    Portnow, Jana
    Lee, Peter
    Mortimer, Joanne
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 11 - 20
12345